Physician

Sebastien Simon Kairouz, M.D.

According to 2025 Medicare claims, Sebastien Kairouz, M.D. (NPI: 1396701009) practices medical oncology in the Decatur, IL market, with the plurality of this provider's patient population coming from Macon, IL. This provider's primary affiliated billing organization is CANCER CARE SPECIALISTS OF CENTRAL ILLINOIS, S.C. (NPI: 1871580142; TIN: 371160364) and primary practice location at 62526-5858. Kairouz is affiliated with the IRCCO (ACO ID: A2619), participating under the MSSP model.

Kairouz's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 720 traditional Medicare patients, billed 297,321 HCPCS/CPT codes, and received $3,955,478 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,791 prescription claims across 311 beneficiaries totaling $5,531,883 in drug costs, led by Revlimid (Lenalidomide). 2023 DME data shows 38 claims. Open Payments data shows 54 records totaling $1,593. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $1,251,613 to $5,531,883. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $19,366 to $354.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	703	547,760	$5,010,724
2016	769	507,891	$5,134,346
2017	853	474,910	$4,631,359
2018	800	344,894	$4,393,551
2019	849	355,317	$5,134,254
2020	747	292,029	$4,292,953
2021	665	256,991	$3,710,151
2022	628	206,576	$3,034,397
2023	602	288,893	$4,342,265
2024	720	297,321	$3,955,478

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	222	1,691	$1,251,613
2016	247	1,749	$1,553,001
2017	258	1,795	$2,137,234
2018	254	1,597	$2,239,429
2019	247	1,497	$2,445,212
2020	238	1,395	$2,732,141
2021	260	1,457	$2,221,270
2022	268	1,419	$3,147,848
2023	267	1,613	$4,467,458
2024	311	1,791	$5,531,883

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	40	365	$31,923
2016	N/R	131	$6,790
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	28	$3,946
2020	N/R	N/R	N/R
2021	N/R	49	$1,593
2022	N/R	N/R	N/R
2023	N/R	38	$597
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	471	943	$85
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	500	866	$12
80053	Blood test, comprehensive group of blood chemicals	458	1,482	$10
36415	Insertion of needle into vein for collection of blood sample	445	1,407	$9
83735	Magnesium level	399	1,286	$7

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	42	1,176	$722,921
Erleada	Apalutamide	42	1,260	$593,524
Venclexta	Venetoclax	39	1,164	$558,682
Pomalyst	Pomalidomide	16	448	$363,883
Promacta	Eltrombopag Olamine	28	840	$352,438

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	54	$1,593	Daiichi Sankyo Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Sebastien Simon Kairouz, M.D.?

Tedicare shows public-source Medicare data for Sebastien Simon Kairouz, M.D. (NPI 1396701009), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Sebastien Simon Kairouz, M.D. have ACO affiliation data?

Sebastien Simon Kairouz, M.D. is shown with ACO affiliation data for IRCCO (MSSP, ACO ID A2619).

What billing organization is linked to Sebastien Simon Kairouz, M.D.?

Sebastien Simon Kairouz, M.D. is linked to CANCER CARE SPECIALISTS OF CENTRAL ILLINOIS, S.C. (billing NPI 1871580142) in the available physician profile data.

Does Sebastien Simon Kairouz, M.D. have Open Payments data?

Sebastien Simon Kairouz, M.D. has 54 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.